Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials

  • Sola, Susana de
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Sánchez Benavides, Gonzalo
  • Benejam, Bessy|||0000-0002-6789-8615
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Rodríguez, Joan
  • Catuara-Solarz, Silvina
  • Sánchez-Gutiérrez, Judit
  • Dueñas-Espin, Ivan
  • Hernandez, Gimena|||0000-0001-5319-3465
  • Peña-Casanova, J. (Jordi)|||0000-0003-1019-1536
  • Langohr, Klaus|||0000-0001-7075-9192
  • Videla, Sebastián|||0000-0001-5049-1379
  • Blehaut, Henry
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Dierssen, Mara|||0000-0003-0853-6865
Abstract: The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome

  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Xicota, Laura|||0000-0003-2832-9214
  • Langohr, Klaus|||0000-0001-7075-9192
  • Sánchez Benavides, Gonzalo
  • de Sola, Susana
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • Rodríguez Soler, Joan|||0000-0003-0062-6401
  • Rodríguez-Morató, Jose|||0000-0002-8133-9983
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Dierssen, Mara|||0000-0003-0853-6865
  • Torre, Rafael de la|||0000-0002-6765-1866
Down syndrome (DS) is an aneuploidy syndrome that is caused by trisomy for human chromosome 21 resulting in a characteristic cognitive and behavioral phenotype, which includes executive functioning and adaptive behavior difficulties possibly due to prefrontal cortex (PFC) deficits. DS also present a high risk for early onset of Alzheimer Disease-like dementia. The dopamine (DA) system plays a neuromodulatory role in the activity of the PFC. Several studies have implicated trait differences in DA signaling on executive functioning based on genetic polymorphisms in the genes encoding for the catechol-O-methyltransferase (COMTVal158Met) and the dopamine transporter (VNTR-DAT1). Since it is known that the phenotypic consequences of genetic variants are modulated by the genetic background in which they occur, we here explore whether these polymorphisms variants interact with the trisomic genetic background to influence gene expression, and how this in turn mediates DS phenotype variability regarding PFC cognition. We genotyped 69 young adults of both genders with DS, and found that VNTR-DAT1 was in Hardy-Weinberg equilibrium but COMTVal158Met had a reduced frequency of Met allele homozygotes. In our population, genotypes conferring higher DA availability, such as Met allele carriers and VNTR-DAT1 10-repeat allele homozygotes, resulted in improved performance in executive function tasks that require mental flexibility. Met allele carriers showed worse adaptive social skills and self-direction, and increased scores in the social subscale of the Dementia Questionnaire for People with Intellectual Disabilities than Val allele homozygotes. The VNTR-DAT1 was not involved in adaptive behavior or early dementia symptoms. Our results suggest that genetic variants of COMTVal158Met and VNTR-DAT1 may contribute to PFC-dependent cognition, while only COMTVal158Met is involved in behavioral phenotypes of DS, similar to euploid population.